E-cadherin is a cell-cell adhesion molecule expressed predominantly by epithelial cells. Reduction or loss of Ecadherin immunoreactivity has been associated with tumour progression in many epithelial cancers, including bladder carcinomas. The ®broblast growth factor receptor 2b (FGFR2b) recognized speci®cally by FGF7 is expressed only by epithelial cells. Recently, decreased expression of FGFR2b protein and mRNA was found to be associated with tumour progression in bladder carcinomas. The purpose of this investigation was to look for a possible relationship between E-cadherin and FGFR2b expression in bladder carcinomas. As decreased E-cadherin immunoreactivity was found to correlate directly with decreased expression at the mRNA level, the possible relationship between E-cadherin and FGFR2b was investigated at the mRNA level using semi-quantitative RT ± PCR in 92 transitional cell carcinomas (TCCs) and four lymph node metastases. All tumours with low E-cadherin expression had low expression of FGFR2b, whereas tumours with low FGFR2b mRNA could express any level of E-cadherin mRNA. The same observation was equally valid for bladder and colon cancer cell lines suggesting that, besides bladder tumours, this relationship could apply to other carcinomas types. These results suggest that a relationship exists between the transcription of the Ecadherin and FGFR2b genes preventing high expression of FGFR2b where expression of E-cadherin is low. We suggest that reduced expression of FGFR2b in conjunction with decreased expression of E-cadherin may contribute to the aggressive behaviour attributable to high grade TCCs.
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Keywords: bladder; E-cadherin; ®broblast growth factor receptor; human, transitional cell carcinoma Tumour progression is accompanied by altered expression of multiple components including growth factors, growth factor receptors and cell adhesion molecules. A large number of studies have indicated that a major cause for invasiveness of carcinoma cells is a disturbance of the integrity of intercellular junctions, often involving functional loss of the cellcell adhesion molecule E-cadherin, the prototypic member of the cadherin superfamily. In vitro an inverse correlation has been found between the level of E-cadherin expression and invasive capacity (Frixen et al., 1991) . Treatment of canine kidney epithelial cells with a monoclonal antibody against E-cadherin results in the acquisition of invasiveness (Behrens et al., 1989) . Conversely, transfection of E-cadherin cDNA in nonexpressing cells abrogates their invasive properties (Frixen et al., 1991; Vleminckx et al., 1991) . Immunohistochemical examination of clinical specimens of many dierent carcinomas including bladder has shown that decreased E-cadherin expression is associated with poor prognosis (Takeichi, 1993; Birchmeier and Behrens, 1994; Bringuier et al., 1993; Otto et al., 1994) . This down-regulation can result from several mechanisms: alteration of transcription (methylation, loss of transactivators or chromatin rearrangement in the regulatory region), posttranslational modi®cations or changes in the interaction of Ecadherin with cytoskeleton anchoring catenin proteins (Giroldi et al., 1994; Gra et al., 1995; Yoshiura et al., 1995; Hennig et al., 1995) . Inactivating mutations have been found commonly only in breast cancer of the lobular type and in diuse type gastric carcinomas (Oda et al., 1994; Becker et al., 1994; Berx et al., 1996; Guilford et al., 1998) .
Urinary bladder transitional cell carcinoma (TCC) is the ®fth most common cancer in men in Western countries. Bladder carcinomas are distinguished as either muscle invasive or super®cial. Invasive tumours are generally associated with poor prognosis, whereas the clinical outcome of super®cial tumours is relatively unpredictable. In order to identify new molecules involved in bladder tumour progression, we have looked for changes in the level of expression of growth factors and their cognate receptors between normal urothelium and bladder carcinomas of dierent stages and grades. We have previously reported that the epithelial-speci®c isoform of the ®broblast growth factor receptor 2b (FGFR2b) was down-regulated in a subset of bladder tumours with poor prognosis (Gil Diez de Medina et al., 1997) . Recently, in an experimental model, it has been shown that FGFR2b can reduce tumour growth (Matsubara et al., 1998) .
Thus, E-cadherin and FGFR2b are two characteristic epithelial components which have tumour suppressor activities and are down-regulated during tumour progression in bladder carcinomas. It was therefore of interest to determine whether there is a relationship between the down-regulation of FGFR2b and E-cadherin in bladder tumours. The demonstration, in this report, of a high correlation between mRNA and protein expression for E-cadherin as previously shown for FGFR2b, enabled us to compare the expression of these two molecules at the mRNA level.
Results and discussion
Forty samples were available for comparison of Ecadherin immunoreactivity and E-cadherin mRNA expression as assessed by semi-quantitative RT ± PCR. Figure 1a shows the expression of E-cadherin mRNA in normal urothelium, and in bladder carcinomas which were divided into three groups, on the basis of normal, heterogeneous or no immunoreactivity for Ecadherin ( Figure 1b ). In general, low relative amounts of E-cadherin mRNA were observed in the samples with no immunoreactivity for E-cadherin, similar Ecadherin mRNA amounts to those observed in normal urothelial specimens were found in samples with normal immunoreactivity for E-cadherin, whereas intermediate amounts of E-cadherin mRNA were observed in samples with heterogeneous labelling with HECD-1. The mean E-cadherin mRNA amounts in the three dierent TCC groups diered signi®cantly (Kruskal-Wallis, non-parametric ANOVA test P=0.0003). This suggests that the decreased immunoreactivity of E-cadherin observed in TCC is mainly due to a decrease in the relative amount of E-cadherin mRNA.
In order to see if there was a relationship between Ecadherin and FGFR2b expression in bladder carcinomas, the values for E-cadherin mRNA were plotted against those for FGFR2b mRNA in a series of 92 transitional cell carcinoma (TCC) of the bladder and four lymph node metastases (Figure 2 ). No linear correlation was found between these two parameters. The dotted line in Figure 2 separates the samples with high or normal amounts of E-cadherin mRNA from the samples with low E-cadherin mRNA, whereas the dashed line separates the samples with high or normal amounts of FGFR2b mRNA from the samples with low amounts of FGFR2b mRNA (see legend of Figure  2 ). There were 67 samples with normal or high Ecadherin and FGFR2b mRNA, 11 samples with normal or high E-cadherin mRNA and low FGFR2b, 18 samples with both low E-cadherin and FGFR2b, but, remarkably, no samples with low Ecadherin mRNA and normal or high FGFR2b. In other words, all the samples with low amounts of Ecadherin mRNA also contained low amounts of FGFR2b mRNA. The same relationship was found if, instead of TBP, GAPDH was used as an internal control for the determination of E-cadherin and FGFR2b mRNA by semi-quantitative RT ± PCR (data not shown). There was a signi®cant trend (P=0.03, Chi-squared test) for association of Ecadherin and FGFR2b negative tumours with high grade (Table 1a) and there was a signi®cant association (P=0.05, Fisher's exact test) for association of Ecadherin and FGFR2b negative tumours with muscle invasive TCCs (Table 1b) . Lymph node metastases were obtained from three patients with primary tumours that expressed normal to high amounts of E-cadherin and FGFR2b. In one patient, neither Ecadherin nor FGFR2b was expressed in either of the two metastatic samples studied. In the other two patients, the metastases retained expression of both markers at an equivalent level to the primary tumour. Figure 1 Correlation between E-cadherin mRNA expression and E-cadherin immunoreactivity in bladder carcinomas. (a) Mean mRNA expression in normal urothelium and in bladder tumours with normal (1), heterogeneous (2) and negative (3) immunohistochemical staining for E-cadherin. Relative expression of Ecadherin mRNA was assessed by semi-quantitative RT ± PCR using TBP as an internal standard. RNA was extracted on a cesium chloride cushion and the amount of E-cadherin mRNA was determined by semi-quantitative RT ± PCR, by comparison with an internal control, an ubiquitous transcription factor TBP (or GAPDH, data not shown) (Radvanyi et al., 1993; Gil Diez de Medina et al., 1997) . Twenty two cycles were used for the coampli®cation of E-cadherin and TBP. The primer sequences of FGFR2b, GAPDH, TBP are as described by Gil Diez de Medina et al. (1997) , the primer sequences of E-cadherin are: GACCAAGTGACCACCTTAGA and GCAGGAATTTG-CAATCCTGCT (5' to 3' direction). After gel electrophoresis, the PCR-ampli®ed products were quanti®ed with a Molecular Dynamics 300 PhosphorImager (Sunnyvale, CA, USA). (b) Evaluation of E-cadherin expression by immunohistochemistry used a classi®cation derived from the works of Shiozaki et al. (1991) and Bringuier et al. (1993) , in which tumours were classi®ed as normal if the staining was similar to that of normal urothelium (1) abnormal if it was heterogeneous when tumours were composed of positive and negative areas (2) or negative if no E-cadherin immunoreactivity was observed (3) an example of tumours of each group is given. Five mm thick frozen sections from these 40 bladder tumours and ®ve normal bladder specimens were ®xed with 4% paraformaldehyde and analysed using mouse monoclonal antibody HECD-1 against E-cadherin (Takara Biomedical, Kyoto, Japan) at a 1/150 dilution and a standard avidin-biotin immunoperoxidase detection system (Vectastain Elite ABC kit, Vector Laboratories, Burlingame, USA) It was of interest to determine if the relationship found between E-cadherin and FGFR2b expression in vivo was maintained in cell lines. We therefore examined the expression of E-cadherin and FGFR2b transcripts in 20 bladder cancer cell lines and one normal urothelial cell line (Southgate et al., 1994) . Figure 3 shows that, as observed with carcinoma samples, there were no bladder cell lines which contained normal or high levels of FGFR2b and low levels of E-cadherin mRNA. Thus, the relationship between E-cadherin and FGFR2b mRNA pertained to both tumour specimens and cell lines. To test the generality of these results, we also compared the level of E-cadherin and FGFR2b mRNA in a series of ten colon cancer cell lines. As observed with TCC samples and derived cell lines, there were no colon cancer cell lines with normal or high expression of FGFR2b mRNA but low E-cadherin mRNA (Figure 3) .
Evidence has accumulated that inactivation of Ecadherin plays a key role in cancer invasion and metastasis. Immunohistochemical examination of clinical tumour specimens of many dierent carcinomas has shown that E-cadherin expression is decreased in advanced cancer and that decreased E-cadherin expression is associated with a poor prognosis. In several cases (papillary thyroid, head and neck and colorectal cancer), E-cadherin immunohistochemistry was shown to be correlated with mRNA expression (Giroldi et al., 1994 ). Our present study shows a good correlation between immunohistochemistry and mRNA in bladder cancer as well, suggesting that the decrease in E-cadherin immunoreactivity results primarily from Figure 2 Relationship between E-cadherin and FGFR2b mRNA in bladder tumours. E-cadherin and FGFR2b mRNA levels were assessed in 92 TCC tumours and four lymph node metastases by semi-quantitative RT ± PCR using TBP as an internal standard (see legend of Figure 1 and Gil Diez de Medina et al., 1997). Ecadherin mRNA levels were plotted against FGFR2b mRNA levels. The dotted (or dashed lines) separate the tumours with low level of E-cadherin (or FGFR2b) with the tumours with normal or high levels. These limits were de®ned for FGFR2b in Gil Diez de Medina et al. (1997) and for E-cadherin in Popov et al. (submitted) , and correspond to 30% of the average values found in normal urothelium. These values corresponded to the tercile of the population for FGFR2b and to the quintile of the population for E-cadherin. The TCCs consisted of 11 Ta, 35 T1, 12 T2, 20 T3, 13 T4 and one of unknown stage; 16 tumours were grade G1, 36 grade G2 and 40 grade G3. The patients' age at diagnosis was in the range of 29 ± 90 years, with a median age of 65.5 years. The bladder tissue was surgically removed by transurethral resection for super®cial TCCs and by radical cystectomy for muscle invasive tumours. Metastases were removed by lymph node dissection. Normal urothelial specimens (n=5) were taken from normal bladder as described in Gil Diez de Medina et al. (1997) Figure 3 Relationship between E-cadherin and FGFR2b mRNA in bladder and colon cell lines. E-cadherin mRNA levels were plotted against FGFR2b mRNA levels. E-cadherin and FGFR2b mRNA levels were measured in 20 cancer bladder cell lines (circles), in one normal urothelial cell line (square) and in ten colon cancer cell lines (triangles) by semi-quantitative RT ± PCR (see Figure 1) . The dotted and dashed lines were as de®ned in Figure 2 . The bladder cancer cell lines (253J, 647V, EJ, EJ138, HCV-29, HT-1197, HT-1376, J82, JON53, RT4, RT112, SCaBER, SD48, T24, TCC SUP, UM-UC3, VM-CUB-1, VM-CUB-3, R-20 and 1207), the normal urothelial cell line (NHU469) and the colon cancer cell lines (COLO-205, COLO-320DM, DLD-1, HT-29, LoVo, SW-480, SW-620, SW-948, SW-1417, WIDr) were obtained from originators' laboratories or from the ATCC. The R-20 and 1207 bladder tumour cell lines were obtained from B Muscatelli and W de Boer (Henri Mondor Hospital, CreÂ teil, France). Cell lines 1207, J82 and JON53 were grown in DMEM/Ham's F12 adjusted to pH 7.2 and supplemented with 10% foetal bovine serum (FBS), 1 mg/ml insulin, 5 nM sodium selenite, 10 mM HEPES, 50 nM 4-hydrocortisone-21 hemisuccinate, 5 mg/ml transferrin, 2 mM L-glutamine, 100 UI penicillin, 100 mg/ml streptomycin; all the other bladder cells were grown in DMEM supplemented with 10% FBS and antibiotics. The colon cell lines were grown in RPMI supplemented with 10% FBS and antibiotics. At 80% con¯uency, cells were washed with cold PBS and lysed in 4 ml of 4 M guanidium isothiocyanate and 0.1 M b-mercaptoethanol in 25 mM sodium citrate pH 7.0 per 75 cm 2¯a sk. The plates were agitated for at least 1 h, the lysate collected and frozen at 7208C until RNA extraction The tumor samples analysed in Figure 2 were grouped according to their grade (a) and stage (b). + (or 7) for mRNA expression higher (or lower) than 30% of the average value found in normal urothelium (see the legend of Figure 2) reduced mRNA expression, although we cannot rule out other additional mechanisms such as post translational mechanisms (proteolytic cleavage, destabilization of the protein due to absence of catenins or phosphorylation). We have recently shown that the epithelial-speci®c FGFR2b receptor is decreased both at the mRNA and the protein levels in a subset of bladder carcinomas. Such decreased expression is associated with poor prognosis (Gil Diez de Medina et al., 1997). It was therefore of interest to determine whether FGFR2b and E-cadherin were down-regulated coordinately in bladder carcinomas. Using a reproducible semi-quantitative RT ± PCR method, we found that all the tumours with low E-cadherin mRNA had also low FGFR2b mRNA whereas tumours with low FGFR2b mRNA could express any amount of Ecadherin mRNA. Two models can account for the observed relationship between E-cadherin and FGFR2b expression, one of which we will call the sequential model, the other being the simultaneous model. In the sequential model, decreased expression of E-cadherin occurs only in cells with attenuated FGFR2b expression. In this case, decreased expression of FGFR2b would be the prior event. In the simultaneous model, decreased expression of FGFR2b can occur independently of decreased Ecadherin expression, but when decreased expression of E-cadherin occurs it is always accompanied by decreased expression of FGFR2b. A common mechanism could account for the simultaneous decreased expression of FGFR2b and E-cadherin such as those which have been proposed for decreased expression of E-cadherin: aberrant methylation of the E-cadherin promoter sequences (Gra et al., 1995; Yoshiura et al., 1995) , loss of transactivators or chromatin rearrangement in the regulatory region (Hennig et al., 1995) . Another possibility would be that decreased E-cadherin expression by lowering intercellular adhesiveness could promote dedierentiation, which in turn could be incompatible with normal expression of FGFR2b. To assess this hypothesis, two bladder carcinoma cell lines expressing E-cadherin (RT112, SD48) were treated with an anti-E-cadherin antibody (Bracke et al., 1993) which induced a rapid epithelial-®broblast-like transition. The fact that the level of FGFR2b did not change after this treatment rules out this hypothesis (data not shown).
E-cadherin and FGFR2b are expressed in many epithelia. Reduced expression of E-cadherin mRNA has been reported in a number of carcinoma types and down-regulation of FGFR2b has been described not only in TCCs but also in cell lines derived from various carcinomas (Rubin et al., 1995) . Our results are intriguing as they suggest that there may be coordination in the transcription of E-cadherin and FGFR2b genes preventing high expression of FGFR2b when E-cadherin expression is low. As both E-cadherin and FGFR2b have tumour suppressor activities, this relationship in gene expression may contribute to tumour progression and to the development of the malignant phenotype. The existence of the same relationship in colon carcinoma cell lines suggests that it may be a more general property and may be true for other carcinomas as well.
Further analyses are necessary to understand the kinetics of decreased expression of the two epithelial markers, E-cadherin and FGFR2b, and their relative importance in tumour invasion and metastasis.
Abbreviations FGFR, ®broblast growth factor receptor; TCC, transitional cell carcinoma; TBP, TATA binding protein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
